Unlocking the mysteries of cancer has always been the driving force behind our research. We aim to be a key player in the fields of solid cancer treatments and the development of immunotherapy.
While gene therapy can be controversial, CarryGenes’ groundbreaking technique of using a synthetic human mini chromosome, with the ability to carry new genetic information, provides a genetic engineering method that maintains the integrity of the subject’s genome within the therapeutic cells.
The overall goal is to be able to use a patient’s own cells to cure their cancer by employing a genetic carrier developed from a process found in nature.
”We believe that our technology could be the next major breakthrough in immunoncology with an estimated success rate of 40-50% as a standalone treatment in solid cancer, and a success rate of 60-80% when combined with existing immune therapeutic agents.”
In comparison, CAR-T and Checkpoint Inhibitor treatments have a success rate of approximately 20% (in non-solid cancer). For these reasons, we predict CarryGenes’ Cromo-T therapy will prove to be a paradigm shift in immunotherapy.
